Validation of a Predictive Risk Equation for Type 2 Diabetes in Families With Risk (DESCENDANCE)
Validation of a Predictive Risk Equation for Type 2 Diabetes in Children With Diabetes to Achieve a Predictive Diagnostic Biochip for the Early Detection of Individuals at Risk in Families.
Considering its epidemic-like development worldwide, associated with modifications in lifestyle, as well as its enormous social and economic weight, the prevention of type II diabetes is certain to be a central concern of health systems within the developed countries in the decades to come. However, while simple obesity concerns the entire population, type 2 diabetes affects only one sub-population at high genetic risk. To be effective and realistic in economic terms, efforts at prevention must be thus targeted towards these subjects at high risk. The key issue involves identifying such subjects early enough so that a strategy of effective prevention can be organized in good time.
Until now, efforts have been concentrated on individuals at risk for diabetes readily identifiable within the general population, typically subjects in the second half of adulthood, presenting abdominal obesity and mild abnormalities of blood sugar. Preventive lifestyle and dietary measures are proposed but are constrictive and difficult to maintain over time, and the results, although they may be significant, remain disappointing, with mere postponement of an outcome which at this stage appears inevitable. The reason is ascribable to excessively tardy intervention, when the pathogenic process has already been ongoing for some ten years and the endocrine function of the pancreas is probably already irreparably impaired.
The alternative thus is earlier intervention, in childhood, adolescence or early adulthood. The problem is to identify individuals at high risk of becoming diabetic at a time when they are presenting no simple clinical or laboratory abnormalities allowing easy diagnosis. The familial character of type 2 diabetes is now well established, and future diabetic subjects are themselves above all the children of diabetic subjects. However, the prevalence of the disease among the descendants of type 2 diabetic subjects is around 20-30% and predictive tools are needed to combat diabetes in these high-risk families.
We propose to create a risk equation using an algorithm to reliably predict children most likely to develop diabetes later in life.
The algorithm will include 3 classes of data:
- The genotype stemming from the genetic characterization of individuals and those their parents;
- Environmental data concerning childhood, especially eating habits and physical activity;
- Data of the mother who was eventually diabetic during pregnancy.
From a methodological standpoint, it would be rather difficult to take blood samples from children and wait some 50 years to determine whether or not they develop diabetes. To circumvent this difficulty, we will recruit subjects in families with a history of type II diabetes:
- Parents alive, including at least one type 2 diabetic subject
- Adult children (aged over 35 years), some of whom are already presenting type II diabetes, and healthy brothers and sisters, who form the control population. Test will be done to determine whether healthy subjects are really safe from the risk of diabetes (HbA1c measurement and glucose load test).
The Descendence study will include 500 families at risk involving about 3000 subjects (1000 subjects with diabetes and 2000 healthy subjects). It is expected to answer the following question: for a child born in such families at risk, what is the probability of developing diabetes later in life, so that early preventive action may be taken
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Besancon、フランス、25030
- Chu Jean Minjoz
-
Bobigny、フランス、93000
- CHU Avicenne
-
Bondy、フランス
- CHU de Bondy
-
Brest、フランス
- CHU de Brest
-
Caen、フランス、14000
- CHU de Caen
-
Evry、フランス、91000
- Ch Sud Francilien
-
Grenoble、フランス、38043
- University Hospital Grenoble
-
Le Kremlin-Bicêtre、フランス、94270
- CHU de Bicêtre
-
Lille、フランス、59037
- CHRU Lille
-
Marseille、フランス、13274
- CHU Marseille Hôpitaux Sud
-
Nancy、フランス、54500
- CHU de Nancy
-
Nantes、フランス、44000
- CHU de Nantes
-
Paris、フランス、75877
- CHU Bichat
-
Reims、フランス
- CHU de Reims
-
Strasbourg、フランス、67000
- Centre Hospitalier Strasbourg
-
Toulouse、フランス、31403
- CHU Toulouse
-
-
-
-
-
Liege、ベルギー、4000
- CHU Sart Tilman Liege
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Families at risk for diabetes defined by the existence of the disease in two successive generations and consists with healthy subject in the two generations.
- Subjects must be aged over 25 years
Exclusion Criteria:
- subject refusing to participate
- pregnant women
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：非ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の：Type 2 diabetic subject
Subject with type 2 diabetes
|
|
|
他の：healthy subject
Healthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations
|
Oral Glucoce Tolerance Test
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Measure of risk of developing type 2 diabetes in at-risk families
時間枠：participants will be followed from the moment where they sign consent form and until they have sent back questionnary and done the blood test, an expected average of 4 weeks
|
Oral Glucose Tolerance Test (only for health volunteers) HbA1c assay (for type 2 diabetic subject)
|
participants will be followed from the moment where they sign consent form and until they have sent back questionnary and done the blood test, an expected average of 4 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。